

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Antengene Corporation Limited

德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF SCIENTIFIC OFFICER

This announcement is made by Antengene Corporation Limited (the “**Company**” or “**Antengene**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group. The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that Dr. Bing Hou (“**Dr. Hou**”) has been appointed as the Chief Scientific Officer of the Company, reporting directly to Dr. Jay Mei, the founder, Chairman, and Chief Executive Officer of the Company.

Dr. Hou’s appointment underscores Antengene’s commitment to strengthening its innovation-driven R&D model as a global biotech company. In this role, Dr. Hou will lead Antengene’s efforts across Drug Discovery, Translational Medicine and Chemistry, Manufacturing and Controls (CMC), with a focus on deepening the Company’s research engine and building a pipeline of next-generation therapeutic candidates with transformational potential.

“We are very pleased to appoint Dr. Bing Hou as Chief Scientific Officer of Antengene. Dr. Hou has made significant contributions to shaping Antengene’s scientific strategy and strengthening our internal research capabilities. Under his leadership, Antengene has built and advanced AnTenGager®, the Company’s proprietary T-cell engager (TCE) 2.0 platform with broad applicability across autoimmune diseases, solid tumors and hematological malignancies, as well as other novel programs and platform technologies that support our next-generation pipeline. The global license agreement Antengene entered into with UCB for ATG-201, a CD19 x CD3 TCE developed from the AnTenGager® platform for B cell-related autoimmune diseases, further highlights the strategic value of Antengene’s proprietary discovery capabilities. As we enter our next stage of growth, we look forward to Dr. Hou’s continued leadership in expanding our innovative pipeline, and bringing forward transformative therapies for patients globally.”, said by Dr. Jay Mei, the founder, Chairman, and Chief Executive Officer of Antengene.

“I am honored and excited to step into the role of Chief Scientific Officer at Antengene. Antengene is advancing a number of highly promising programs across oncology and autoimmune diseases, and I believe we are well positioned to build a next-generation pipeline grounded in rigorous biology, differentiated mechanisms and platform innovation. Looking ahead, we will continue to focus on programs with the potential to address significant unmet medical needs, including T cell engagers developed from our proprietary AnTenGager® platform; ATG-125, a B7-H3 x PD-L1 bispecific antibody-drug conjugate (ADC) designed to combine ADC and immuno-oncology mechanisms; and ATG-207, a globally first-in-class α CD3-TGF- β bifunctional fusion protein for T cell-driven autoimmune diseases. I look forward to continuing to work closely with the Antengene team to translate our differentiated science and platform capabilities into a robust pipeline of innovative medicines.”, said by Dr. Hou, the Chief Scientific Officer of Antengene.

The biographical details of Dr. Hou are set out below:

Dr. Hou received his Ph.D. in Biomedicine from the University of Leeds in the United Kingdom. He has published multiple high-impact research papers as first author or corresponding author in leading journals including Nature, Science Advances, and Cancer Research. He has filed more than 40 patent applications for novel therapeutics. As an inventor and/or principal leader, he has advanced multiple first-in-class or best-in-class drug candidates into various stages of clinical development.

Since joining the Company in 2019, Dr. Hou has been a key member of the Company’s scientific leadership team, and prior to this appointment, served as Vice President, Head of Discovery Science & Translational Medicine. During his tenure, he has built and led a high-caliber discovery organization, helped guide the Company’s R&D initiatives, advanced internally discovered programs into clinical development, and played an important role in establishing newly developed proprietary platforms designed to support future innovation programs.

By the order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, May 20, 2026

As at the date of this announcement, the Board comprises Dr. Jay Mei and Mr. Donald Andrew. Lung as executive Directors; and Ms. Jing Qian, Mr. Sheng Tang and Dr. Rafael Fonseca as independent non-executive Directors.